HCW Biologics (HCWB) Director Garrett Scott T Buys 7,736 Shares

What Happened Garrett Scott T, a director of HCW Biologics, purchased 7,736 shares of HCWB common stock on July 29, 2026, at $2.58 per share for a total of $19,998. The shares were acquired directly from the issuer in a private placement (transaction code P), which is a purchase and generally considered a more bullish signal than a sale.

Key Details

• Transaction date and price: 2026-07-29; 7,736 shares at $2.58 each (total ~$19,998).
• Filing date: 2026-07-31 (filed within the typical Form 4 reporting window).
• Shares owned after transaction: Not specified in the Form 4; filing notes Garrett is deemed to beneficially own shares held by Garrett Capital Partners, LLC (see footnote F2).
• Footnote F1: Shares purchased in a private placement exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D. Reporting person is also entitled to receive common warrants exercisable for up to 7,736 shares; issuance of those warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). If issued, the warrants would be exercisable immediately and expire 5.5 years from issuance.
• Footnote F2: Beneficial ownership includes shares held by Garrett Capital Partners, LLC.

Context This was a direct purchase from the company in a private placement rather than an open-market buy. The additional common warrants referenced are conditional on stockholder approval, so they are not yet outstanding. The dollar amount is modest (~$20k), so while purchases by insiders can be informative, this single small purchase should be weighed with other insider activity and company developments.